Skip to main content
Explore URMC
menu

Muscle-Invasive Bladder Cancer: Durvalumab in combination with Gemcitabine and Cisplatin (Given Before the Primary Treatment) and Durvalumab Alone (Given After the Primary Treatment)

Research Question:
What is the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer?

Basic Study Information

Purpose:
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment (given before the primary treatment) and Durvalumab Alone for Adjuvant Treatment (given after the primary treatment) in Patients with Muscle-Invasive Bladder Cancer

Location: University of Rochester Medical Center
Study Reference #: IGUB19002

Lead Researcher (Principal Investigator)

Lead Researcher: Chunkit Fung

Study Contact Information

Study Coordinator: Park Bogan
Phone: (585) 276-4415
Email: Park_Bogan@URMC.Rochester.edu

Additional Study Details

Return to Search